1. Academic Validation
  2. Bactericidal and anti-quorum sensing activity of repurposing drug Visomitin against Staphylococcus aureus

Bactericidal and anti-quorum sensing activity of repurposing drug Visomitin against Staphylococcus aureus

  • Virulence. 2024 Dec;15(1):2415952. doi: 10.1080/21505594.2024.2415952.
Ruolan Wu 1 Yuan Wu 1 Pingyun Wu 1 Huilong Li 1 Pengfei She 1
Affiliations

Affiliation

  • 1 Department of Laboratory Medicine, The Third Xiangya Hospital of Central South University, Changsha, China.
Abstract

With the growing Antibiotic resistance in Staphylococcus aureus, it is imperative to develop innovative therapeutic strategies against new targets to reduce selective survival pressures and incidence of resistance. In S. aureus, interbacterial communication relies on a quorum sensing system that regulates gene expression and physiological activities. Here, we identified that Visomitin, an antioxidant small molecule, exhibited bactericidal efficacy against methicillin-resistant S. aureus and its high tolerance phenotypes like intracellular bacteria and persister cells without inducing resistance. Critically, sub-minimal inhibitory concentrations (sub-MICs) of Visomitin could serve as a potent quorum-quencher reducing virulence production (such as haemolysin and staphyloxanthin), along with inhibiting biofilm formation, self-aggregation, and colony spreading of S. aureus. These effects were probably mediated by interfering with the S. aureus accessory gene regulator quorum sensing system. In summary, our findings suggest that Visomitin shows dual antimicrobial effects, including bactericidal effects at the concentrations above MIC and quorum sensing inhibition effects at sub-MICs, which holds promise for treating MRSA-related refractory infections.

Keywords

Methicillin-resistant Staphylococcus aureus; Visomitin; antimicrobial; biofilm; haemolysis; quorum sensing.

Figures
Products
我们的 Cookie 政策

我们使用 Cookies 和类似技术以提高网站的性能和提升您的浏览体验,部分功能也使用 Cookies 帮助我们更好地理解您的需求,为您提供相关的服务。 如果您有任何关于我们如何处理您个人信息的疑问,请阅读我们的《隐私声明》